OR WAIT null SECS
September 02, 2022
Pharma loses battle to block price negotiations, but implementation faces many challenges.
August 30, 2022
Novavax’s COVID-19 vaccine, Nuvaxovid, can now be given to adolescents aged 12 to 17 in the UK.
August 29, 2022
The European Union publishes long-awaited changes to Annex 1.
August 23, 2022
NICE has recommended the use of Tavneos (avacopan) in combination with rituximab or cyclophosphamide regimen.
Kapruvia (difelikefalin) has been granted approval by Swissmedic as a treatment for moderate-to-severe pruritis associated with CKD.
EMA has accepted the marketing authorization application for an oral fixed-dose combination treatment as an initial treatment for adults with AML.
August 16, 2022
Charles River has received approval to commercially produce allogeneic cell therapy products for distribution in Europe from EMA.
The UK’s MHRA has granted marketing authorization for Novartis’ radioligand therapy, Pluvicto, for the treatment of advanced prostate cancer in Great Britain.
August 15, 2022
The United Kingdom has approved Moderna’s bivalent COVID-19 vaccine, which targets the original variant and Omicron.
August 12, 2022
Moderna and the European Commission have amended their agreement to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the company’s Omicron-containing bivalent vaccines for supply in 2022.